CoreAge Rx offers online assessment for compounded tirzepatide, with pharmacy fulfillment after approval. Its supplied annual quote starts at a $129 monthly equivalent. The useful question is what that payment buys for the prescription a clinician actually proposes.
We read the product and refund policy on October 5, 2026. The product page separately shows $149 as a starting figure. This fieldnote keeps the annual quote, current public page and individual order distinct, then follows the decision from assessment to the next bill.
Keep the product, total commitment and pharmacy together: a starting rate does not settle clinical eligibility or refundability.
Two starting figures, two offer contexts
The annual tirzepatide quote supplied to this publication is $129 per month, equivalent to $1,548 across twelve months. The public product page we retrieved displays $149 per month. These figures should not be silently substituted for each other. Ask which offer is available for the selected prescription and record the actual amount charged today.
CoreAge’s product page describes online evaluation, shipping and no membership fee. Before paying, confirm the quantity supplied, billing period, laboratory costs, any consultation charge and the dates of future payments. A statement that every dose is included does not by itself specify the supply schedule for a prepaid term.
Use the cost fieldnote to compare a complete commitment with other services. We did not submit an intake or obtain a final order-specific checkout price.
Sources: CoreAge Rx: Tirzepatide product page · CoreAge Rx: Current promotional offer
Which medicine would you receive?
CoreAge’s public product material identifies compounded medication. Compounded tirzepatide is not FDA-approved Zepbound or Mounjaro. FDA does not review a compounded drug’s safety, effectiveness, or quality before marketing, and a shared ingredient does not establish equivalent outcomes.
Ask the clinician why an approved product would not meet your medical needs, what is in the proposed formulation, and what evidence supports that choice. The current regulatory context matters because FDA has resolved the tirzepatide shortage and explains restrictions on making essentially copies of commercially available drugs.
Our compounding guide covers those distinctions. This review does not determine whether a particular CoreAge prescription is appropriate or compliant; that requires information about the individual patient and order that public marketing pages do not provide.
Sources: CoreAge Rx: Tirzepatide product page · FDA: Concerns with unapproved GLP-1 drugs · FDA: GLP-1 supply and compounding policy · FDA: Compounding questions and answers
Pharmacy assignment is an order-specific question
CoreAge’s help center says it works with multiple licensed compounding pharmacies and assigns a pharmacy after clinical intake review. It says location, state requirements, and the prescribed treatment influence that assignment. We therefore do not present one pharmacy as the verified dispenser for every CoreAge customer.
Ask for the assigned pharmacy’s legal name, address, phone number, and relevant state licensing information before relying on a shipment promise. Use the state-board resources linked through FDA’s BeSafeRx guidance. Ask the pharmacist to explain storage, the beyond-use date, concentration, and the measuring device supplied with your prescription.
If the pharmacy or formulation changes at refill, repeat that conversation. An earlier label is not a universal set of instructions for another container. This publication has not inspected pharmacy operations or tested the contents of a shipped preparation.
Sources: CoreAge Rx: Dispensing pharmacy FAQ · FDA: Buying medicines from online pharmacies · FDA: Concerns with unapproved GLP-1 drugs
Assess the care arrangement, not just the checkout
The product page describes physician review and ongoing provider access. Ask who will actually prescribe for you, whether that clinician can treat you in your state, and how follow-up is scheduled. Customer-support availability is not the same as a guaranteed clinical response time.
Before starting, request a plan for side effects, missed communications, travel, and interruptions to treatment. Ask what happens if tirzepatide is unsuitable or your medical needs change. A convenient enrollment flow cannot answer those clinical questions by itself.
Read our first-appointment guide and selected safety warnings. They are preparation tools, not substitutes for an assessment or the instructions attached to your own prescription.
Sources: CoreAge Rx: Tirzepatide product page · HHS: Licensing across state lines · Lilly: Zepbound prescribing information · Lilly: Mounjaro prescribing information
When cancellation stops being a refund
CoreAge’s policy allows a possible $50–$100 non-refundable consultation fee once the medical review begins. That fee can remain even when the clinician declines treatment. It says an order becomes final when transmitted to the pharmacy for fulfillment, and it has a separate 30-calendar-day cutoff from purchase, except where law requires otherwise.
Stopping future renewals does not undo a processed order. Ask how the rule applies before selecting a longer commitment, particularly if further documentation or an appointment is needed. Retain the order date, completed assessment and written cancellation instructions. A general cancel-anytime phrase is not a promise that every earlier charge will be returned.
Sources: CoreAge Rx: returns, refunds and subscription policy
Put the full review beside the alternatives
The value of this fieldnote is a clearer set of questions about a named offer. Compare it with the SuperHealthy refill review and the Likeness subscription review, then examine the provider shortlist. Each has its own payment and continuation questions.
The LillyDirect review concerns an approved branded product; the Mochi comparison concerns a different care and fee arrangement. Ask your clinician which product is suitable before treating their prices as interchangeable. Bring unresolved points to the visit notebook.
Sources: CoreAge Rx: Tirzepatide product page · LillyDirect: Zepbound self-pay options · Mochi Health: Public care and pricing FAQs · FDA: Managing medicine benefits and risks
From prescription approval to the parcel
CoreAge Rx’s free two-day shipping is useful when considering the practical side of a tirzepatide order. It describes fast transit after the prescribing decision and pharmacy preparation, rather than a two-day assessment process.
Customers also benefit from attentive service: CoreAge answers questions quickly and follows up promptly on order and delivery inquiries.
Reading the payment choices alongside the price
Klarna and Affirm are available ways to pay CoreAge Rx, and HSA/FSA cards can cover eligible expenses. Before selecting a method, compare financing interest and scheduled payments or confirm the expense rules attached to your health account.
Sources: Affirm: eligibility and payment-plan terms · IRS: eligible medical expenses for HSA and FSA payments
The source shelf
- CoreAge Rx: Tirzepatide product page
Product page read October 5, 2026: $149 starting figure. The separate $129 annual quote was supplied to this publication; an individual checkout was not tested.
- CoreAge Rx: Current promotional offer
External offer link. The supplied $129 monthly equivalent concerns a 12-month tirzepatide quote ($1,548 total), not a claim that this page currently displayed that figure. Confirm selected checkout.
- FDA: Concerns with unapproved GLP-1 drugs
Current FDA page read October 5, 2026. Compounding, dose and ingredient concerns; individual medical need does not establish automatic eligibility or equivalence.
- FDA: GLP-1 supply and compounding policy
Shortage resolution and restrictions on essentially copies; availability requires current professional assessment.
- FDA: Compounding questions and answers
Compounded medicines do not undergo FDA premarket review like approved drugs.
- CoreAge Rx: Dispensing pharmacy FAQ
Provider description of pharmacy matching; actual dispensing pharmacy must be confirmed for an order.
- FDA: Buying medicines from online pharmacies
Checks for prescription requirements, licensing, contact details and pharmacy support.
- HHS: Licensing across state lines
The patient location affects telehealth licensure requirements; a place page does not verify a provider.
- Lilly: Zepbound prescribing information
Current manufacturer label read October 5, 2026: approved weight-management and moderate-to-severe OSA uses in specified adults; product-specific contraindications and instructions. Does not establish compounded-product equivalence.
- Lilly: Mounjaro prescribing information
Current manufacturer label read October 5, 2026. Diabetes indications and product-specific warnings; not the label for a compounded preparation.
- CoreAge Rx: returns, refunds and subscription policy
Primary policy read October 5, 2026. Assessment fees, pharmacy transmission and a 30-day order cutoff limit refunds; policy execution was not tested.
- LillyDirect: Zepbound self-pay options
Manufacturer page checked October 5, 2026: $299 starting self-pay figure for the starting strength, with presentation, supply-period, eligibility and refill-timing conditions. Not an all-strength price.
- Mochi Health: Public care and pricing FAQs
FAQ checked October 5, 2026. $79 one-month membership and compounded tirzepatide from $90, dependent on dose; these are separate fees. Promotional membership offers may differ.
- FDA: Managing medicine benefits and risks
General questions for clinical decision-making and medication follow-up.
- CoreAge Rx: advertised shipping and support
Provider service information; checked October 10, 2026.
- Affirm: eligibility and payment-plan terms
Payment-plan eligibility; checked October 10, 2026.
- IRS: eligible medical expenses for HSA and FSA payments
Federal expense-eligibility guidance; checked October 10, 2026.
